Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
New and experimental HIV treatments
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Biktarvy Showed High Efficacy and a Demonstrated Tolerability Profile Through 96 Weeks

Published
03 October 2018
From
Gilead press release
New and experimental HIV treatments
HIV drug Symtuza® receives NHS England funding

The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that NHS England (NHSE) will provide critical funding for Symtuza® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with a body weight of at least 40 kg.

Published
28 September 2018
From
Pharmafield
The search for a cure
Powerful antibodies suppress HIV for months, could simplify treatment

Two studies in small numbers of people show for the first time that infusions of two powerful anti-HIV antibodies can completely suppress the virus for several months.

Published
28 September 2018
From
Science
The search for a cure
Proof-of-concept HIV immunotherapy study passes Phase 1 safety trial

Preliminary results from a phase I clinical trial have demonstrated the safety and tolerability of a cell therapy involving the ex vivo expansion of T cells and their subsequent infusion into HIV-infected individuals previously treated with antiretroviral therapy (ART). The study appears September 21st in the journal Molecular Therapy.

Published
24 September 2018
From
Science Daily
New and experimental HIV treatments
European advisory group backs Merck's HIV meds Delstrigo and Pifeltro

The European Medicines Agency's advisory group CHMP adopts a positive opinion backing approval for Merck's (NYSE:MRK) DELSTRIGO (doravirine, lamivudine and tenofovir disoproxil fumarate) and PIFELTRO (doravirine) for the treatment of adults with chronic HIV-1 infection.

Published
24 September 2018
From
Seeking Alpha
New and experimental HIV treatments
NIH launches study to test combination antibody treatment for HIV infection

The early phase clinical trial will evaluate whether periodic infusions of two highly potent, HIV-specific, broadly neutralizing antibodies (bNAbs)—3BNC117 and 10-1074—are safe in people living with HIV.

Published
21 September 2018
From
National Institutes of Health
New and experimental HIV treatments
ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV

ViiV Healthcare today announced submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.

Published
16 September 2018
From
ViiV press release
New and experimental HIV treatments
Doravirine Sets a New Standard for NNRTIs — But What Role in HIV Treatment Today?

Doravirine has enough advantages that it is a useful advance in HIV therapy, if not a transformational one.

Published
13 September 2018
From
NEJM Journal Watch
New and experimental HIV treatments
DNA technology provides novel strategy for delivery of complex anti-HIV agent

Scientists have applied synthetic DNA technology to engineer a novel eCD4-Ig anti-HIV agent and to enhance its potency in vivo, providing a new simple strategy for constructing complex therapeutics for infectious agents as well as for diverse implications in therapeutic delivery.

Published
06 September 2018
From
Science Daily
New and experimental HIV treatments
Elpida™ Included in Essential Drugs List for HIV-1 in Russia

Viriom's Elsulfavirine (Elpida™)-based regimens for treatment of HIV-1 infection will be available to all patients and physicians in both regionally and federally funded programs in Russia.

Published
06 September 2018
From
PR Newswire (press release)
← Prev1...34567...58Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.